IDT Australia Ltd
- Country
- Ownership
- -
- Employees
- 1.8K
- Market Cap
- -
- Introduction
IDT Corp. operates as a holding company. The firm engages in the distribution and market of communications and payment services. It operates through the following segments: Fintech, National Retail Solutions, Net2phone, Traditional Communications, and Corporate. The Fintech segment is involved in international money remittance and related value transfer services. The National Retail Solutions segment refers to an operator of a nationwide POS network providing independent retailers with store management software, electronic payment processing, and other ancillary merchant services. The Net2phone segment consists of net2phone's cloud communications and contact center offerings. The Traditional Communications segment includes IDT Digital Payments, which enables customers to transfer airtime and bundles of airtime, messaging, and data to international and domestic mobile accounts, BOSS Revolution Calling, an international long-distance calling service marketed primarily to immigrant communities in the United States and Canada, and IDT Global, a wholesale provider of international voice and SMS termination and outsourced traffic management solutions to telecoms worldwide. The company was founded by Howard S. Jonas in August 1990 and is headquartered in Newark, NJ.
Clinical Trials
0
Trial Phases
0 Phases
Drug Approvals
12
Drug Approvals
Temozolomide Capsules 5 mg (280375)
- Product Name
- Temozolomide Capsules 5 mg
- Approval Date
- Sep 16, 2016
Temozolomide Capsules 20 mg (280377)
- Product Name
- Temozolomide Capsules 20 mg
- Approval Date
- Sep 16, 2016
Temozolomide Capsules 180 mg (280380)
- Product Name
- Temozolomide Capsules 180 mg
- Approval Date
- Sep 16, 2016
Temozolomide Capsules 140 mg (280379)
- Product Name
- Temozolomide Capsules 140 mg
- Approval Date
- Sep 16, 2016
Temozolomide Capsules 100 mg (280431)
- Product Name
- Temozolomide Capsules 100 mg
- Approval Date
- Sep 16, 2016
Temozolomide Capsules 250 mg (280384)
- Product Name
- Temozolomide Capsules 250 mg
- Approval Date
- Sep 16, 2016
Doxazosin mesilate Tablets 4 mg (238897)
- Product Name
- Doxazosin mesilate Tablets 4 mg
- Approval Date
- May 25, 2015
Doxazosin mesilate Tablets 1 mg (238895)
- Product Name
- Doxazosin mesilate Tablets 1 mg
- Approval Date
- May 25, 2015
- Prev
- 1
- 2
- Next
Clinical Trials
News
Ribbon Bio Strengthens Commercial Leadership with Jeff Fitzgerald Appointment as Global Sales Head Amid MiroSynth™ DNA Launch
• Ribbon Bio has appointed Jeff Fitzgerald as Vice President, Global Head of Sales to drive commercial growth as the company launches its first product, MiroSynth™ DNA Molecules. • Fitzgerald brings over a decade of commercial leadership experience from companies including ArcherDx and IQVIA, where he demonstrated success in scaling operations and delivering revenue growth. • MiroSynth™ DNA utilizes Ribbon Bio's proprietary algorithm-driven technology and enzymatic assembly process to deliver highly complex and accurate synthetic DNA for applications in biopharma and life sciences.